Health and Healthcare
Hydroxychloroqine Could Be Back in Play With Recent Taiwan FDA Filing
Published:
Taiwan Liposome Co. Ltd (NASDAQ: TLC) shares shot higher on Friday after the company announced it was making a regulatory filing for a COVID-19 treatment that has been at the center of some controversy.
The firm is filing an Investigational New Drug (IND) Application to the Taiwan Food and Drug Administration (TFDA) for TLC19 hydroxychloroquine liposome inhalation suspension for the treatment of COVID-19.
Hydroxychloroquine (HCQ) has been at the heart of much debate over the safety and efficacy when applied to patients with COVID-19. Recent studies suggest that “HCQ can prevent the acidification of intracellular organelles, inhibit lysosomal release of viral genome and interfere with the glycosylation of the angiotensin-converting enzyme-2 (ACE2) receptor on the host cell, reducing the binding efficiency between the receptor and spike protein on the surface of the coronavirus and thereby reducing the chances of COVID-19 infection and replication.” Therefore, on the molecular and cellular levels, HCQ has been shown to achieve antiviral activity against SARS-CoV-2.
On the other hand, the U.S. FDA emphasized the importance of translating in vitro antiviral activity to appropriate clinical dosing regimens and concluded that “antiviral effect against SARS-Cov-2 was not likely achievable with a safe oral dosing regimen” of HCQ due to dose confinement by potential cardiotoxicity. The U.S. FDA revoked emergency use authorization for HCQ, and recent clinical trials studying orally administered HCQ were halted.
TLC19, administered through a vibration mesh nebulizer, can achieve antiviral effect with a miniscule dose compared to orally administered HCQ, while lowering blood and heart exposure. Ultimately, this gives TLC19 the potential to treat COVID-19.
Taiwan Liposome stock traded up over 41% at $7.20, in a 52-week range of $2.48 to $12.65. The consensus price target is $12.75.
24/7 Wall St.Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.